This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iliskovic, N. Articles by Singal, P. K. Search for Related Content PubMed PubMed Citation Articles by Iliskovic, N. Articles by Singal, P. K.

American Journal of Pathology, Vol 150, 727-734, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Lipid lowering: an important factor in preventing adriamycin-induced heart failure

N Iliskovic and PK Singal
Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Canada.

The contribution of lipid lowering in protection against adriamycin cardiomyopathy achieved by probucol, an antioxidant and a lipid- lowering drug, was assessed by comparing its beneficial effects with that of lovastatin, another lipid-lowering drug with no known antioxidant properties. Adriamycin (cumulative dose, 15 mg/kg body weight) was given to rats in 6 equal injections (intraperitoneally) over a period of 2 weeks. Probucol (cumulative dose, 120 mg/kg body weight) or lovastatin (cumulative dose, 48 mg/kg body weight) was given in 12 equal injections (intraperitoneally) before and concurrent with adriamycin. After 3 weeks of post-treatment with adriamycin, congestive heart failure, ascites, congested liver, and depressed cardiac function were seen. Adriamycin treatment decreased glutathione peroxidase activity and increased lipid peroxidation. Adriamycin increased plasma triglycerides, total cholesterol, and high- and low-density lipoproteins. Myocardial triglycerides and total cholesterol were also increased. Probucol completely prevented the development of congestive heart failure and normalized myocardial and plasma triglycerides and total cholesterol, and significantly decreased plasma high- and low- density lipoproteins. Lovastatin significantly attenuated but did not completely prevent cardiomyopathic changes due to adriamycin. Lovastatin decreased plasma total cholesterol and low-density lipoproteins as well as myocardial triglycerides and total cholesterol. Plasma triglycerides and high-density lipoproteins were still high in the adriamycin plus lovastatin group. Probucol improved glutathione peroxidase activity and reduced lipid peroxidation whereas lovastatin had no effect on these adriamycin-induced changes. These data suggest that adriamycin cardiomyopathy is associated with an antioxidant deficit as well as increased myocardial and plasma lipids. Complete protection by probucol against adriamycin-induced congestive heart failure may be due to the unique combination of its antioxidant and lipid-lowering properties.

This article has been cited by other articles:

				M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour, and U. Lang The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis Cardiovasc Res, October 1, 2008; 80(1): 69 - 77. [Abstract] [Full Text] [PDF]

				K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]

				M. Tabuchi, H. To, H. Sakaguchi, N. Goto, A. Takeuchi, S. Higuchi, and S. Ohdo Therapeutic Index by Combination of Adriamycin and Docetaxel Depends on Dosing Time in Mice Cancer Res., September 15, 2005; 65(18): 8448 - 8454. [Abstract] [Full Text] [PDF]

				H. To, M. Shin, M. Tabuchi, H. Sakaguchi, A. Takeuchi, N. Matsunaga, S. Higuchi, and S. Ohdo Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice Clin. Cancer Res., January 15, 2004; 10(2): 762 - 769. [Abstract] [Full Text] [PDF]

				K. Suzuki, B. Murtuza, L. Heslop, J. E. Morgan, R. T. Smolenski, N. Suzuki, T. A. Partridge, and M. H. Yacoub Single fibers of skeletal muscle as a novel graft for cell transplantation to the heart J. Thorac. Cardiovasc. Surg., May 1, 2002; 123(5): 984 - 992. [Abstract] [Full Text] [PDF]

				K. Suzuki, B. Murtuza, N. Suzuki, R. T. Smolenski, and M. H. Yacoub Intracoronary Infusion of Skeletal Myoblasts Improves Cardiac Function in Doxorubicin-Induced Heart Failure Circulation, September 18, 2001; 104(90001): I-213 - 217. [Abstract] [Full Text] [PDF]

				T. Nakamura, Y. Ueda, Y. Juan, S. Katsuda, H. Takahashi, and E. Koh Fas-Mediated Apoptosis in Adriamycin-Induced Cardiomyopathy in Rats : In Vivo Study Circulation, August 1, 2000; 102(5): 572 - 578. [Abstract] [Full Text] [PDF]

				W. Feleszko, I. Mlynarczuk, E. Z. Balkowiec-Iskra, A. Czajka, T. Switaj, T. Stoklosa, A. Giermasz, and M. Jakóbisiak Lovastatin Potentiates Antitumor Activity and Attenuates Cardiotoxicity of Doxorubicin in Three Tumor Models in Mice Clin. Cancer Res., May 1, 2000; 6(5): 2044 - 2052. [Abstract] [Full Text]

				O. J. Arola, A. Saraste, K. Pulkki, M. Kallajoki, M. Parvinen, and L.-M. Voipio-Pulkki Acute Doxorubicin Cardiotoxicity Involves Cardiomyocyte Apoptosis Cancer Res., April 1, 2000; 60(7): 1789 - 1792. [Abstract] [Full Text]

				P. K Singal, N. Khaper, V. Palace, and D. Kumar On the role of coenzyme Q10 in cardiovascular diseases Cardiovasc Res, July 1, 1999; 43(1): 250 - 251. [Full Text] [PDF]

				P. K. Singal and N. Iliskovic Doxorubicin-Induced Cardiomyopathy N. Engl. J. Med., September 24, 1998; 339(13): 900 - 905. [Full Text] [PDF]